Ask Onix
Migraine's long-standing mystery begins to unravel
A debilitating neurological condition affecting over 1.2 billion people worldwide is finally shedding its outdated reputation as a mere headache, as researchers uncover its intricate biological roots.
The human toll of migraine
For millions, migraine is not just pain-it's a relentless cascade. A dull, liquid pressure builds behind one eye, radiating to the jaw, sometimes burning, sometimes throbbing. Movement worsens it. Light and sound become unbearable. Nausea, vertigo, or even temporary vision distortions called auras may follow. The longer treatment is delayed, the harder the attack is to control, often returning once medication wears off.
Despite ranking as the second leading cause of global disability, migraine has long been dismissed as a minor ailment, particularly for women, who make up three-quarters of patients. Centuries of stigma-once labeled a "feminine whim" or "hysteria"-have stunted research and funding, leaving critical questions unanswered.
From stigma to science: A shifting paradigm
Experts now classify migraine as a disorder, not just a headache, with "attacks" as flare-ups of an underlying neurological condition. The economic and personal costs are staggering: in the UK alone, migraine drains £12 billion ($17 billion) annually from the economy, with individuals facing higher risks of job loss, early retirement, and financial strain during their prime working years (ages 25-54).
"It's probably among the most poorly understood neurological disorders-or disorders in general."
Gregory Dussor, Chair in Behavioural and Brain Sciences, University of Texas at Dallas
Symptoms vs. triggers: A blurred line
Migraine's symptoms are notoriously diverse. While headaches dominate, patients also report nausea, extreme fatigue, food cravings, excessive yawning, or sensory hypersensitivity. Auras-visual disturbances like jagged light flashes-affect about 25% of sufferers. Triggers are equally varied: stress, lack of sleep, certain foods, hormonal changes, or even the relief of stress (a common cause of weekend attacks).
However, emerging research suggests many so-called triggers may actually be early symptoms. For example, cravings for chocolate or cheese might reflect subconscious responses to the onset of an attack, not its cause. Similarly, sensitivity to light or scents could stem from neurological changes already underway.
"What if, instead, during the premonitory phase of an attack, you're sensitive to scent? You notice smells you wouldn't normally."
Peter Goadsby, Professor of Neurology, King's College London
The brain's role: Electrical waves and hidden signals
Scientists have long debated whether migraine originates in blood vessels or the brain. While blood vessel dilation occurs during attacks, it's likely a symptom, not the root cause. The leading theory now points to cortical spreading depression-a slow, abnormal electrical wave that suppresses brain activity and triggers inflammation. In March 2025, researchers captured this wave in real time via electrodes in a patient's brain, tracing its 80-minute spread from the visual cortex (explaining light sensitivity) to other regions.
Yet this wave doesn't explain all symptoms. A 2025 study found the hypothalamus-a brain region tied to stress and sleep-activates a full day before an attack. Meanwhile, pain is felt in the meninges, the brain's protective membrane, where immune cells may overreact to allergens or acidity changes, sparking inflammation.
Genetics and the search for biomarkers
Genetics play a major role, with studies estimating 30-60% of migraine risk is hereditary. In 2022, geneticist Dale Nyholt identified 123 "risk Snips"-tiny DNA variations linked to migraine-by comparing 100,000 patients to 770,000 controls. Some genes overlap with those for depression, diabetes, and brain structure size, hinting at shared pathways.
The most promising breakthrough involves calcitonin gene-related peptides (CGRPs), neuromodulators found at unusually high levels in migraine patients, even between attacks. Drugs targeting CGRPs have revolutionized treatment: in a 2025 study, 70% of patients saw a 75% reduction in attack frequency, and 23% became attack-free.
"We're just scraping the surface of what's happening with migraine."
Amynah Pradhan, Director, Centre for Clinical Pharmacology, Washington University in St. Louis
A spectrum disorder with no single cure
Migraine is increasingly viewed as a chronic, whole-body condition, with no one-size-fits-all solution. Hormonal fluctuations, immune responses, and environmental factors all intertwine. While CGRP drugs offer hope, scientists stress the need for deeper research into biomarkers to predict treatment responses.
For now, patients like the author-who experiences weekly attacks tied to her menstrual cycle-find solace in progress. "Science is slowly chipping away at the mystery," she writes, "and though there isn't a single answer, there might be a variety of options that come together instead."
What's next
This article is part of a two-part series on migraine disorder. Part two, publishing Friday, 6 February, will explore the latest treatments and emerging therapies.
